By Fineline Cube 
Daiichi Sankyo Company, Limited (TYO: 4568) and AstraZeneca PLC (NASDAQ: AZN) announced U.S. Food and Drug Administration (FDA) approval for their co-developed antibody drug conjugate (ADC) Datroway (datopotamab deruxtecan) as a treatment for adult patients with unresectable or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy.
Regulatory Approval Summary
| Parameter | Detail |
|---|---|
| Drug Name | Datroway (datopotamab deruxtecan) |
| Indication | Unresectable or metastatic TNBC (PD-1/PD-L1 inhibitor ineligible) |
| Regulatory Agency | U.S. FDA |
| Approval Basis | Phase III TROPION-Breast02 study |
| Drug Class | TROP2-targeting antibody drug conjugate (ADC) |
| Partnership | Daiichi Sankyo (Japan) / AstraZeneca (Global except Japan) |
Pivotal Phase III TROPION-Breast02 Results
Overall Survival (Primary Endpoint)
- Median OS Benefit: 5.0 months improvement vs. chemotherapy
- Hazard Ratio (HR): 0.79 (95% CI: 0.64–0.98; p = 0.0290)
- Statistical Significance: Met primary endpoint with clinically meaningful benefit
Progression-Free Survival (Key Secondary Endpoint)
- Risk Reduction: 43% reduction in disease progression or death
- Hazard Ratio (HR): 0.57 (95% CI: 0.47–0.69; p < 0.0001)
- Clinical Impact: Highly statistically significant improvement
Treatment Response Rates
- Objective Response Rate (ORR): 64% with Datroway vs. 30% with chemotherapy
- Response Magnitude: More than double the response rate compared to standard care
Expanding Indication Portfolio
Datroway represents a cornerstone of the partners’ ADC strategy, with an expanding global indication portfolio:
Previous Approvals
- Japan (December 2024): HR-positive, HER2-negative unresectable/recurrent breast cancer post-chemotherapy
- US, EU, China (2025): Same HR+/HER2- breast cancer indication as Japan approval
- US (June 2025): Locally advanced/metastatic EGFR-mutated NSCLC post-EGFR TKI and platinum chemotherapy
Target Profile
- Molecular Target: TROP2 (trophoblast cell-surface antigen 2)
- Mechanism: Antibody drug conjugate delivering cytotoxic payload specifically to TROP2-expressing tumor cells
- Therapeutic Rationale: TROP2 is highly expressed in multiple solid tumors including TNBC, making it an attractive target for precision therapy
Market Implications & Commercial Outlook
The TNBC approval significantly expands Datroway’s addressable patient population in the U.S., adding to its established presence in HR+/HER2- breast cancer and NSCLC. With approximately 40,000 new TNBC cases annually in the U.S., and a substantial portion ineligible for immunotherapy, this approval creates a major commercial opportunity.
The 5.0-month overall survival benefit positions Datroway as a new standard of care in this difficult-to-treat population, where treatment options have been limited and outcomes historically poor. The robust efficacy data across multiple endpoints—survival, progression-free survival, and response rates—demonstrates comprehensive clinical benefit.
Daiichi Sankyo and AstraZeneca’s ADC platform continues to validate its potential, with Datroway joining Enhertu in establishing the companies as leaders in next-generation targeted cancer therapies.
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, clinical development, and commercial expectations. Actual results may differ due to risks including market competition, manufacturing supply, pricing negotiations, and evolving treatment guidelines.-Fineline Info & Tech